Sihui Song

Sihui Song

Auto-generated profile, based on publicly available information

Sihui Song

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2026 in Science
Verified
Journal Article
Closed access
YCYun Chen
Yun Chen
YLYizhou Liu
Yizhou Liu
KNKhai Nguyen
Khai Nguyen
JWJunjie Wu
Junjie Wu
SSSihui Song
Sihui Song
MCMarco Colonna
Marco Colonna
Alzheimer’s disease (AD) is the leading cause of dementia and is characterized by progressive amyloid accumulation followed by tau-mediated neurodegeneration. Despite advances in anti-amyloid immunotherapies, important limitations remain, highlighting the need for new therapeutic strategies. Here, we introduce anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) and validate their function in vitro. We show that two CAR-A designs reduce amyloid and associated pathology after plaque formation and prevent early plaque deposition in vivo. Single-nucleus RNA sequencing shows that CAR-A treatment induces a distinct glial response to amyloid pathology involving coordinated activity of astrocytes and microglia. Each construct additionally elicits distinctive, receptor-specific effects in astrocytes or microglia. Together, these findings support the therapeutic potential of CAR-A as a disease-modifying strategy for AD.

1 December 2025 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
KRKaleigh F. Roberts
Kaleigh F. Roberts
ELEric C. Landsness
Eric C. Landsness
JRJustin Reese
Justin Reese
DEDonald Elbert
Donald Elbert
GSGabrielle Strobel
Gabrielle Strobel
RBRandall J. Bateman
Randall J. Bateman
Despite major advances in Alzheimer's disease and related diseases (ADRD) research, the translation of discoveries into impactful clinical interventions remains slow. Overwhelming data complexity, fragmented knowledge, and prolonged research cycles hinder progress in understanding and treating neurodegenerative diseases. Artificial intelligence (AI) offers a promising path forward, particularly when developed as a scientist-in-the-loop system that collaborates with researchers throughout the scientific discovery process. This paper introduces the concept of an AI Biomedical Scientist, an intelligent platform designed to support literature synthesis, hypothesis generation, experimental design, and data interpretation. This platform aims to function as a holistic scientific partner, integrating diverse biomedical data and expert reasoning to accelerate discovery. We review commercial and academic efforts and introduce targeted Minimum Viable Products (MVPs) needed for general biomedical research lab utilization of AI, such as robust and accurate tools for literature and data analysis, negative data models, and virtual peer review, with a longer-term vision of foundation models trained directly on biomedical datasets. In AD and neurodegeneration research, such tools are anticipated to deliver efficiency gains ranging from modest improvements in specific research tasks to potential multi-fold accelerations in discovery workflows as systems mature and scale. This review examines the technical foundations, challenges, and anticipated impacts of AI and aims to inform and engage researchers in utilizing these systems to transform biomedical discovery, starting with AD and extending to other complex conditions.